ACADIA Pharmaceuticals Inc logo

ACADIA Pharmaceuticals Inc(ACAD)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
3-STAR RATING
PASS
LAST CLOSE
$17.83
11/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ACAD

11/18/2026: ACAD (3-star) is currently NOT-A-BUY. Pass it for now.

ACADIA Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in central nervous system disorders and rare diseases. Its primary business strengths rest on established commercial products, notably NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, which drive steady top-line revenues. The core investment story centers on expanding these flagship franchises into international markets and additional clinical indications. Key risks include revenue concentration, regulatory hurdles, and potential pipeline setbacks. The stock suits growth-oriented investors comfortable with biotech volatility, while market participants should monitor ongoing prescription trends and clinical developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitACADIA offers solid double-digit top-line expansion driven by the commercial scaling of NUPLAZID and DAYBUE.
Momentum investorMixed fitMomentum fit is conditional on positive clinical readouts and breakout price trends amidst biotech sector volatility.
Value investorMixed fitThe company trades at reasonable valuation multiples relative to commercial revenues, though typical biotech pipeline risks apply.
Dividend investorWeak fitACADIA retains earnings to fund clinical trials and commercial growth and does not pay a dividend.
Low-risk investorWeak fitBiotechnology equities carry inherent clinical trial, regulatory, and price volatility risks unsuitable for low-risk strategies.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stock prices frequently experience sharp fluctuations around regulatory decisions and clinical data announcements.
Valuation riskMediumValuations depend heavily on the continued commercial uptake and patent protection of core revenue drivers.
Competition risk (CNS and rare disease therapeutics)Medium / highThe company faces continuous competition from alternative therapies and emerging pipeline assets developed by industry peers.
Business qualityMedium / highACADIA features established commercial products, growing revenues, and validated regulatory expertise.
Dividend incomeLow / noneThe firm distributes no dividend income, focusing entirely on capital appreciation and reinvestment.
Execution riskMediumSuccessful commercial execution and pipeline progression remain vital for sustaining long-term financial growth.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.17B USD
Price to earnings Ratio 8.64
1Y Target Price 30.32
Price to earnings Ratio 8.64
1Y Target Price 30.32
Volume (30-day avg) 2.4M shares
Beta 0.89
52 Weeks Range 15.86 - 30.96
Updated Date 11/18/2026
52 Weeks Range 15.86 - 30.96
Updated Date 11/18/2026
Dividends yield (FY) -
Basic EPS (TTM) 2.12

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.0%
Active BUY / eligible
67 / 108
30-Day BUY Count Change
+22
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
43.6%
Active BUY / eligible
17 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 43.23%
Avg. Invested days 52
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/18/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ACAD receives a 4-star rating, supported by solid company fundamentals, and strong analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
ACAD has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+72.7%) and solid cash generation (FCF margin 9.8%) are partially offset by very low insider ownership of 0.33%.

Financial Health Rating

★★★★★
ACAD's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 50.2%). Operating efficiency is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is ACAD's strongest growth driver at +72.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+11.9%, solid) is also solid, while free-cash-flow growth (-33.1%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 98.0% and approximately 74.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.33%, which materially reduces the ownership score.

Top 5 Institutional Investors

Baker Bros Advisors LP 24.83%
BlackRock Inc 13.03%
State Street Corp 5.25%
Vanguard Portfolio Management, LLC 5.11%
RTW INVESTMENTS, LLC 4.13%

Unit Economics (Per $1K Revenue)

★★★★★
ACAD generates approximately $917 of gross profit, $98 of operating income, and $98 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins and weak cash conversion support a 3-star rating, while capital efficiency is strong.

Economic Dimensions

★★★★★
Effective Tax Rate: -181.49% (Tax Credit)

Quantitative Style Profile

★★★★★
ACAD has a high-quality, liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltSmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Neurological Franchise (NUPLAZID)Commercial sales of NUPLAZID (pimavanserin) for Parkinson's disease psychosis in the United States.This serves as the foundational cash-flow engine for the company.
Rare Disease Franchise (DAYBUE)Commercial sales of DAYBUE (trofinetide) for Rett syndrome across approved markets.This represents the primary growth catalyst and secondary revenue pillar.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-04
When After Market
Estimate 0.19
Actual 0.31

Profitability

Profit Margin 30.13%
Operating Margin (TTM) 10.18%

Management Effectiveness

Return on Assets (TTM) 4.89%
Return on Equity (TTM) 31.43%

Valuation

Trailing PE 8.64
Forward PE 21.05
Enterprise Value 2.34B
Price to Sales(TTM) 2.63
Enterprise Value 2.34B
Price to Sales(TTM) 2.63
Enterprise Value to Revenue 1.94
Enterprise Value to EBITDA 17.3
Shares Outstanding 172.83M
Shares Floating 129.32M
Shares Outstanding 172.83M
Shares Floating 129.32M
Percent Insiders 0.33
Percent Institutions 98.04

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.